Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreatic lipase is a key digestive enzyme secreted by the pancreas into the small intestine, where it catalyzes the hydrolysis of dietary triglycerides into monoglycerides and free fatty acids—an essential step for efficient fat absorption. Structurally, it consists of two domains: an N-terminal catalytic domain containing an α/β-hydrolase fold with a catalytic triad (serine 152, aspartic acid 176, histidine 263), and a C-terminal domain important for binding cofactors such as colipase. The enzyme's activity depends on interfacial activation—a conformational change that exposes its active site upon contact with lipid-water interfaces. Pancreatic lipase belongs to a broader family that includes hepatic and gastric/lingual lipases but has unique substrate specificity crucial for human nutrition. It serves as an important therapeutic target in obesity management through pharmacological inhibition.
Inhibition of enzymatic hydrolysis of dietary triglycerides, reducing absorption of fats from the gastrointestinal tract
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreatic lipase enzyme (PL).